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aprescription fordrugsduringanout-patient visit and12.04%reportedhavingpaid for
the medicine. The total out-of-pocket expenditure in 2010 was USD$134,937. The dif-
ference inmean expenditurewas statistically significant showing higher expenditure
among women compared to men (p-value 0.0001). Statistical differences were also
found across age groups (F-test16.46); the highest mean expenditure was observed
in persons aged 60 years and older, followed by individuals in the age group 51-60 and
0-9 years old. Results from the logistic regression model show that younger men and
women are more likely than those in the middle-aged groups to spend on medicine.
People living in regions of very high socio-economicmarginality spendmore on drugs
than their better off counterparts. Individuals registered at their family medical care
unit are less likely to make expenditures for drugs than the non-registered. Illness
increases the probability of drug spending by 0.065. CONCLUSIONS: The out-of-
pocket drug expenditure among ambulatory care users varies according to social,
economic and demographic factors at the individual and regional levels.
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OBJECTIVES: One of the most challenging problems for pharmaceutical policy is
how to pay for very expensive new drugs for rare diseases, known as “Orphan
drugs” (ODs). Aims of this work were to compare the expenditure and utilization of
ODs among five European Union Countries (France, Germany, Italy, Spain, UK) and
identify the ATC group with the major impact on Italian ODs expenditure and
utilization. METHODS: European database from IMS and the AIFA internal data-
base were consulted for the period 2009-2010 according to the ODs approved by
European Medicines Agency. RESULTS: In all 5EU both utilization and expenditure
increased in the year 2010 compared to 2009 ranging respectively around 13%-28%
for the expenditure and around 7%-17% for the utilization. Italy is the third after
Germany (917 Ml €) and France (828 Ml €) for the expenditure and the second after
Germany (22Ml standard units) for utilization. 80% of the ODs authorised by EMA is
available in Italy, the remaining 20% is not accessible (marketing reasons). During
2010 Italian expenditure for ODs amounted to 5,5 Ml €, with an increase by 19%
compared to 2009. According to the utilization, the value of ODs amounted to 20Ml
standard units, with an increase of 15% compared to 2009. “L” ATC code (antineo-
plastic) represents the highest expenditure (63% of total ODs) and utilization (60%
of total ODs). Within “L” ATC group, Imatinib is the most used molecule (146 Ml €
and 8,5 Ml standard units) with an average cost/patient/year of 38,500€ (assuming
weight 70kg) ranging from 5,700€ (Anagrelide) and 44,500€ (Nilotinib).
CONCLUSIONS: Results suggest that ODs expenditure and utilization is rapidly
growing up, particularly for some ATC groups. The increase of ODs’ utilization is a
common challenge among EU countries in order to guarantee a balance between
patient access and budget sustainability.
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OBJECTIVES: Evidence shows that high Medicare spending is not associated with
better health outcomes at a regional level and that high spending in hospitals is not
associatedwith better process quality. The relationship between hospital spending
and inpatient mortality is less well understood. We seek to determine the associ-
ation between hospital spending and risk-adjusted inpatientmortality.METHODS:
Retrospective cohort study. Setting: Database of discharge records from 1999 to
2008 for 208 California hospitals included in The Dartmouth Atlas of Health Care.
Patients: 2,545,352 patients hospitalized during 1999 to 2008 with 1 of 6 major
medical conditions. Measurements: Inpatient mortality rates among patients ad-
mitted to hospitals with varying levels of end-of-life hospital spending. RESULTS:
For each of 6 diagnoses at admission—acute myocardial infarction, congestive
heart failure, acute stroke, gastrointestinal hemorrhage, hip fracture, and pneu-
monia—patient admission tohigher-spending hospitals was associated with lower
risk-adjusted inpatient mortality. During 1999 to 2003, for example, patients ad-
mittedwith acutemyocardial infarction to California hospitals in the highest quin-
tile of hospital spending had lower inpatient mortality than did those admitted to
hospitals in the lowest quintile (odds ratio, 0.862 [95% CI, 0.742 to 0.983]). Predicted
inpatient deaths would increase by 1831 if all patients admitted with acute myo-
cardial infarction were cared for in hospitals in the lowest quintile of spending
rather than the highest. The association be- tween hospital spending and inpatient
mortality did not vary by region or hospital size. Limitation: Unobserved predictors
of mortality create uncertainty about whether greater inpatient hospital spending
leads to lower inpatientmortality. CONCLUSIONS:Hospitals that spendmore have
lower inpatient mor- tality for 6 common medical conditions.
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OBJECTIVES: The aim of this research was to assess the first year of purchasing
pharmaceuticals in the public health sector in Jordan through the joint procure-
ment process for the 4 participating parties in comparison with purchasing phar-
maceuticals independently before the institution of joint procurement.METHODS:
The first tender under the joint procurement process was issued in 2007 for
antibiotics, antiHIY medications, and antituberculosis agents, which represent
15% of the annual pharmaceutical publicsector purchases in Jordan. A research
committee solicited lists of purchased quantities and final purchase prices of
these pharmaceuticals obtained in 2006 by each participating group and in 2007
through the joint procurement process. The quantity-comparison method was
used to compare the costs of drugs purchased in 2006 and 2007, and estimated
cost savings were calculated for each product for each party for 2006 and 2007
under the assumption that the same quantities purchased by each participating
party in 2006 would be purchased through joint procurement (prices of 2007).
RESULTS: Purchasing through the joint procurement process achieved an esti-
mated savings of 2.4%. This savings increased to 8.9% after excluding 1 item (a
cephalosporin), the raw material price of which increased markedly in 2007
compared with 2006 because of an international shortage of raw materials
CONCLUSIONS: Based on these initial findings, applying a joint procurement sys-
tem for pharmaceuticals in the public health sector in Jordan has potential to
reduce expenditures for the purchase of medicines and provide treatment contin-
uously throughout the year.
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OBJECTIVES:Whenpatients takemedications as prescribed, they aremore likely to
achieve clinical goals and reduce their use of otherwise avoidable healthcare ser-
vices. A growing literature suggests that good medication adherence can also re-
duce healthcare costs for these patients. Our objective was to review the literature
to determine for which diseases the evidence for cost offsets was strongest, and
identify why some studies show no cost offsets.METHODS:We conducted a liter-
ature review on medical cost offsets associated with medication adherence. Key
words searched were (medication adherence OR medication compliance) AND
(medical care costs OR cost savings OR cost offset OR healthcare costs). We
limited the search to English language articles published between 1/1/2005-3/31/
2010. Studies were included if they reported the findings of original research.
RESULTS: We identified 573 article titles, of which 100 met the inclusion criteria.
Overall, 44 studies directly measured both medication adherence and costs, and of
them 81% found statistically significant reductions in costs associated with better
adherence. The range of cost offsets varied by disease, with the greatest offsets noted
for congestive heart failure (costs were $4000-$8000 less per year for patients with a
medication possession ratio [MPR] 80%), diabetes (range was $3700-$5700 less for
thosewith anMPR80%), and hypertension (rangewas $549-$3900 less for thosewith
an MPR80%). Characteristics of studies where findings were cost neutral among
adherent patients included: conditions with high medication costs such as multiple
sclerosis, and diseases where spending was shifted frommedical care to prescription
drugswithout increasing total costs such as depression and asthma. CONCLUSIONS:
Many studies confirm the clinical benefits ofmedications and their ability to reduce
utilization. A strong body of new studies now link those benefits to cost-offsets.
Even when cost-offsets are not found, medications tend to be cost neutral.
PHP43
FINANCING HEALTH CARE IN NEPAL
Shrestha DL
Chhatrapati Free Clinic (Hospital), Kathmandu, Nepal
OBJECTIVES: To review and assess the current practices of financing health care in
Nepal, and drawpossible alternative strategies for the payment alongwith delivery
of efficient and equitable health care.METHODS: Literatures review on the financ-
ing mechanisms and their compatibility to deliver efficient health care, globally,
and current practices inNepal. RESULTS:Nepal’s total expenditure on health (TEH)
is still below 10 % of the gross domestic product, albeit marked improvements in
health outcomes in the last 10 years. About 62% and 17% of the total population
meet their health expenses by out of pocket (OOP) payment and government
funded social health insurance (covering civil servants and maternal health ser-
vices), respectively; remaining are supported donor funding.Whilst, 0.4% of private
expenditure on health is supported by prepayment (private) plans, a huge popula-
tion remain uncovered with any protective plans. CONCLUSIONS: As no country
has a single mechanism to finance health care, the challenge of choosing un-
surpassed payment module is almost imputable. With large proportion of TEH
dominated by OOP payment, it has huge implications in efficiency and equity of
health care services at different levels. As improvements in national economy and
large urbanizationmight be a long term plan, increasing reliability and dependability
on tax financing can be an immediate measure to reduce dependence on OOP pay-
ment. Scrutinizing the community health insurance programs and their promotion,
along with closemonitoring of successful social health insurance in developed coun-
tries may be judicious to strengthen equitable health care. Weakening governance,
fragile political leadership and paucity in honesty among the stakeholders has pro-
pelled social health insurance far beyond the reach for theNepalesepopulation.More-
over, there is an utmost need to restructure available resources from high- cost, low-
impact interventions to low-cost, high-impact essential health care services, while
improving effectiveness and efficiency.
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